ZYUS Life Sciences Raises C$15–16M via 23.8–25.4M-Unit Private Placement
ZYUS Life Sciences launched a brokered private placement of 23.8–25.4 million units at C$0.63 each, raising C$15–16 million. Each unit includes one common share and 0.5 warrant exercisable at C$0.85 for 24 months, with 5% agent commission and warrants, to fund Trichomylin® Phase 2a completion and Phase 2b preparation.
1. LIFE Offering Launch and Structure
ZYUS Life Sciences has launched a brokered private placement of between 23.8 million and 25.4 million Units at C$0.63 per Unit for aggregate gross proceeds of C$15 million to C$16 million. Each Unit consists of one common share and one-half of a warrant, with each full warrant exercisable for one additional share at C$0.85 for 24 months. The placement is being led by Canaccord Genuity Corp. as sole bookrunner and includes a syndicate of agents.
2. Agent Compensation and Incentives
ZYUS will pay a cash commission of 5% on gross proceeds to the Agents and issue Agent warrants equal to 5% of Units sold, exercisable at the Offering price for 36 months. Subscriptions from the President’s List (up to C$5 million) will incur a reduced commission and warrant rate of 2.5%. The Lead Agent will also receive a corporate finance fee of 2% cash and 2% in corporate finance warrants, excluding President’s List subscriptions.
3. Use of Proceeds and Timing
Net proceeds will fund the completion of the Phase 2a trial of Trichomylin® softgel capsules, preparation for Phase 2b, and general corporate purposes. Closing is expected on or about January 29, 2026, subject to TSXV and other regulatory approvals. Units and underlying securities will not be subject to hold periods under Canadian securities laws due to the listed issuer financing exemption.